Although deregulation of IGF pathway through amplification or overexpression of IGF2 is involved in another mucosal-origin tumor, CRC [17], clinical relevance of IGF2R mutations is still controversial [42]. The gene discussed is IGF2R; the disease is colorectal carcinoma.